Pregnancy Management in HIV Viral Controllers: Twenty Years of Experience
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Demographics
3.2. Baseline Immune and Virologic Parameters
3.3. Ante and Perinatal Maternal Management
3.4. Post-Partum and Neonatal Management
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Deeks, S.G.; Walker, B.D. Human immunodeficiency virus controllers: Mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007, 27, 406–416. [Google Scholar] [CrossRef]
- Navarrete-Munoz, M.A.; Restrepo, C.; Benito, J.M.; Rallon, N. Elite controllers: A heterogeneous group of HIV-infected patients. Virulence 2020, 11, 889–897. [Google Scholar] [CrossRef]
- Yang, O.O.; Cumberland, W.G.; Escobar, R.; Liao, D.; Chew, K.W. Demographics and natural history of HIV-1-infected spontaneous controllers of viremia. Aids 2017, 31, 1091–1098. [Google Scholar] [CrossRef]
- Okulicz, J.F.; Lambotte, O. Epidemiology and clinical characteristics of elite controllers. Curr. Opin. HIV AIDS 2011, 6, 163–168. [Google Scholar] [CrossRef]
- Sajadi, M.M.; Constantine, N.T.; Mann, D.L.; Charurat, M.; Dadzan, E.; Kadlecik, P.; Redfield, R.R. Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J. Acquir. Immune Defic. Syndr. 2009, 50, 403–408. [Google Scholar] [CrossRef]
- Berg, M.G.; Olivo, A.; Harris, B.J.; Rodgers, M.A.; James, L.; Mampunza, S.; Niles, J.; Baer, F.; Yamaguchi, J.; Kaptue, L.; et al. A high prevalence of potential HIV elite controllers identified over 30 years in Democratic Republic of Congo. EBioMedicine 2021, 65, 103258. [Google Scholar] [CrossRef]
- Gabagaya, G.; Rukundo, G.; Amone, A.; Wavamunno, P.; Namale-Matovu, J.; Lubega, I.; Nakabiito, C.; Namukwaya, Z.; Nolan, M.; Malamba, S.S.; et al. Prevalence of undetectable and suppressed viral load in HIV-infected pregnant women initiating Option B+ in Uganda: An observational study nested within a randomized controlled trial. BMC Infect. Dis. 2021, 21, 907. [Google Scholar] [CrossRef]
- Almeida, J.R.; Price, D.A.; Papagno, L.; Arkoub, Z.A.; Sauce, D.; Bornstein, E.; Asher, T.E.; Samri, A.; Schnuriger, A.; Theodorou, I.; et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 2007, 204, 2473–2485. [Google Scholar] [CrossRef]
- Adland, E.; Hill, M.; Lavandier, N.; Csala, A.; Edwards, A.; Chen, F.; Radkowski, M.; Kowalska, J.D.; Paraskevis, D.; Hatzakis, A.; et al. Differential Immunodominance Hierarchy of CD8(+) T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. J. Virol. 2018, 92, e01685-17. [Google Scholar] [CrossRef]
- Lopalco, L. CCR5: From Natural Resistance to a New Anti-HIV Strategy. Viruses 2010, 2, 574–600. [Google Scholar] [CrossRef]
- Dominguez-Molina, B.; Ferrando-Martinez, S.; Tarancon-Diez, L.; Hernandez-Quero, J.; Genebat, M.; Vidal, F.; Munoz-Fernandez, M.A.; Leal, M.; Koup, R.; Ruiz-Mateos, E. Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance-Supercontrollers. Front. Immunol. 2018, 9, 2897. [Google Scholar] [CrossRef]
- Nabi, R.; Moldoveanu, Z.; Wei, Q.; Golub, E.T.; Durkin, H.G.; Greenblatt, R.M.; Herold, B.C.; Nowicki, M.J.; Kassaye, S.; Cho, M.W.; et al. Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy. PLoS ONE 2017, 12, e0180245. [Google Scholar] [CrossRef]
- Jiang, C.; Lian, X.; Gao, C.; Sun, X.; Einkauf, K.B.; Chevalier, J.M.; Chen, S.M.Y.; Hua, S.; Rhee, B.; Chang, K.; et al. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature 2020, 585, 261–267. [Google Scholar] [CrossRef]
- Borrell, M.; Fernandez, I.; Etcheverrry, F.; Ugarte, A.; Plana, M.; Leal, L.; Garcia, F. High rates of long-term progression in HIV-1-positive elite controllers. J. Int. AIDS Soc. 2021, 24, e25675. [Google Scholar] [CrossRef]
- Hunt, P.W.; Brenchley, J.; Sinclair, E.; McCune, J.M.; Roland, M.; Page-Shafer, K.; Hsue, P.; Emu, B.; Krone, M.; Lampiris, H.; et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 2008, 197, 126–133. [Google Scholar] [CrossRef]
- Brusca, R.M.; Hanna, D.B.; Wada, N.I.; Blankson, J.N.; Witt, M.D.; Jacobson, L.P.; Kingsley, L.; Palella, F.J., Jr.; Budoff, M.; Brown, T.T.; et al. Subclinical cardiovascular disease in HIV controller and long-term nonprogressor populations. HIV Med. 2020, 21, 217–227. [Google Scholar] [CrossRef]
- Pereyra, F.; Lo, J.; Triant, V.A.; Wei, J.; Buzon, M.J.; Fitch, K.V.; Hwang, J.; Campbell, J.H.; Burdo, T.H.; Williams, K.C.; et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. Aids 2012, 26, 2409–2412. [Google Scholar] [CrossRef]
- Garcia, P.M.; Kalish, L.A.; Pitt, J.; Minkoff, H.; Quinn, T.C.; Burchett, S.K.; Kornegay, J.; Jackson, B.; Moye, J.; Hanson, C.; et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. New Engl. J. Med. 1999, 341, 394–402. [Google Scholar] [CrossRef]
- Quinn, T.C.; Wawer, M.J.; Sewankambo, N.; Serwadda, D.; Li, C.; Wabwire-Mangen, F.; Meehan, M.O.; Lutalo, T.; Gray, R.H. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med. 2000, 342, 921–929. [Google Scholar] [CrossRef]
- Cohen, M.S.; Chen, Y.Q.; McCauley, M.; Gamble, T.; Hosseinipour, M.C.; Kumarasamy, N.; Hakim, J.G.; Kumwenda, J.; Grinsztejn, B.; Pilotto, J.H.; et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N. Engl. J. Med. 2016, 375, 830–839. [Google Scholar] [CrossRef]
- Rodger, A.J.; Cambiano, V.; Bruun, T.; Vernazza, P.; Collins, S.; van Lunzen, J.; Corbelli, G.M.; Estrada, V.; Geretti, A.M.; Beloukas, A.; et al. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. Jama 2016, 316, 171–181. [Google Scholar] [CrossRef]
- Ioannidis, J.P.; Abrams, E.J.; Ammann, A.; Bulterys, M.; Goedert, J.J.; Gray, L.; Korber, B.T.; Mayaux, M.J.; Mofenson, L.M.; Newell, M.L.; et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J. Infect. Dis. 2001, 183, 539–545. [Google Scholar] [CrossRef]
- Mofenson, L.M.; Lambert, J.S.; Stiehm, E.R.; Bethel, J.; Meyer, W.A., 3rd; Whitehouse, J.; Moye, J., Jr.; Reichelderfer, P.; Harris, D.R.; Fowler, M.G.; et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N. Engl. J. Med. 1999, 341, 385–393. [Google Scholar] [CrossRef]
- Maternal viral load and vertical transmission of HIV-1: An important factor but not the only one. The European Collaborative Study. Aids 1999, 13, 1377–1385. [CrossRef]
- Sperling, R.S.; Shapiro, D.E.; Coombs, R.W.; Todd, J.A.; Herman, S.A.; McSherry, G.D.; O’Sullivan, M.J.; Van Dyke, R.B.; Jimenez, E.; Rouzioux, C.; et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med. 1996, 335, 1621–1629. [Google Scholar] [CrossRef]
- Townsend, C.L.; Byrne, L.; Cortina-Borja, M.; Thorne, C.; de Ruiter, A.; Lyall, H.; Taylor, G.P.; Peckham, C.S.; Tookey, P.A. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011. Aids 2014, 28, 1049–1057. [Google Scholar] [CrossRef]
- Connor, E.M.; Sperling, R.S.; Gelber, R.; Kiselev, P.; Scott, G.; O’Sullivan, M.J.; VanDyke, R.; Bey, M.; Shearer, W.; Jacobson, R.L.; et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med. 1994, 331, 1173–1180. [Google Scholar] [CrossRef]
- Kintu, K.; Malaba, T.R.; Nakibuka, J.; Papamichael, C.; Colbers, A.; Byrne, K.; Seden, K.; Hodel, E.M.; Chen, T.; Twimukye, A.; et al. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): An open-label, randomised controlled trial. Lancet HIV 2020, 7, e332–e339. [Google Scholar] [CrossRef]
- Neely, M.N.; Benning, L.; Xu, J.; Strickler, H.D.; Greenblatt, R.M.; Minkoff, H.; Young, M.; Bremer, J.; Levine, A.M.; Kovacs, A. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2007, 44, 38–42. [Google Scholar] [CrossRef]
- Cu-Uvin, S.; DeLong, A.K.; Venkatesh, K.K.; Hogan, J.W.; Ingersoll, J.; Kurpewski, J.; De Pasquale, M.P.; D’Aquila, R.; Caliendo, A.M. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. Aids 2010, 24, 2489–2497. [Google Scholar] [CrossRef]
- Bull, M.; Mitchell, C.; Soria, J.; Styrchak, S.; Williams, C.; Dragavon, J.; Ryan, K.J.; Acosta, E.; Onchiri, F.; Coombs, R.W.; et al. Genital Shedding of Human Immunodeficiency Virus Type-1 (HIV) When Antiretroviral Therapy Suppresses HIV Replication in the Plasma. J. Infect. Dis. 2020, 222, 777–786. [Google Scholar] [CrossRef]
- Tuomala, R.E.; O’Driscoll, P.T.; Bremer, J.W.; Jennings, C.; Xu, C.; Read, J.S.; Matzen, E.; Landay, A.; Zorrilla, C.; Blattner, W.; et al. Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J. Infect. Dis. 2003, 187, 375–384. [Google Scholar] [CrossRef]
- Rutland, E.; Mani, R. Management of pregnancy in an HIV elite controller. Int. J. STD AIDS 2010, 21, 604–605. [Google Scholar] [CrossRef]
- de Ruiter, A.; Mercey, D.; Anderson, J.; Chakraborty, R.; Clayden, P.; Foster, G.; Gilling-Smith, C.; Hawkins, D.; Low-Beer, N.; Lyall, H.; et al. British HIV Association and Children’s HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med. 2008, 9, 452–502. [Google Scholar] [CrossRef]
- Taylor, G.P.; Clayden, P.; Dhar, J.; Gandhi, K.; Gilleece, Y.; Harding, K.; Hay, P.; Kennedy, J.; Low-Beer, N.; Lyall, H.; et al. British HIV Association guidelines for the management of HIV infection in pregnant women 2012. HIV Med. 2012, 13 (Suppl. 2), 87–157. [Google Scholar] [CrossRef]
- Gilleece, D.Y.; Tariq, D.S.; Bamford, D.A.; Bhagani, D.S.; Byrne, D.L.; Clarke, D.E.; Clayden, M.P.; Lyall, D.H.; Metcalfe, D.R.; Palfreeman, D.A.; et al. British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018. HIV Med. 2019, 20 (Suppl. 3), s2–s85. [Google Scholar] [CrossRef]
- Churchill, D.; Waters, L.; Ahmed, N.; Angus, B.; Boffito, M.; Bower, M.; Dunn, D.; Edwards, S.; Emerson, C.; Fidler, S.; et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med. 2016, 17 (Suppl. 4), s2–s104. [Google Scholar] [CrossRef]
- Taylor, G.P.; Lyall, E.G.; Mercey, D.; Smith, R.; Chester, T.; Newell, M.L.; Tudor-Williams, G. British HIV Association guidelines for prescribing antiretroviral therapy in pregnancy (1998). Sex. Transm. Infect. 1999, 75, 90–97. [Google Scholar] [CrossRef]
- Townsend, C.L.; Cortina-Borja, M.; Peckham, C.S.; Tookey, P.A. Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990–2006. BJOG Int. J. Obstet. Gynaecol. 2008, 115, 1078–1086. [Google Scholar] [CrossRef]
- Rasi, V.; Peters, H.; Sconza, R.; Francis, K.; Bukasa, L.; Thorne, C.; Cortina-Borja, M. Trends in antiretroviral use in pregnancy in the UK and Ireland, 2008–2018. HIV Med. 2022, 23, 397–405. [Google Scholar] [CrossRef]
- Briand, N.; Warszawski, J.; Mandelbrot, L.; Dollfus, C.; Pannier, E.; Cravello, L.; Nguyen, R.; Matheron, I.; Winer, N.; Tubiana, R.; et al. Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era? Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2013, 57, 903–914. [Google Scholar] [CrossRef]
- European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: A randomised clinical trial. Lancet 1999, 353, 1035–1039. [Google Scholar] [CrossRef]
- European Collaborative Study; Boer, K.; England, K.; Godfried, M.H.; Thorne, C. Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: Changing practices in Western Europe. HIV Med. 2010, 11, 368–378. [Google Scholar] [CrossRef]
- World Health Organization. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV; World Health Organization: Geneva, Switzerland, 2015.
- Raffe, S.; Curtis, H.; Tookey, P.; Peters, H.; Freedman, A.; Gilleece, Y.; British, H.I.V.A.A.; Standards, S.-C. UK national clinical audit: Management of pregnancies in women with HIV. BMC Infect. Dis. 2017, 17, 158. [Google Scholar] [CrossRef]
- Peters, H.B.L.F.K.; Sconza, R.; Thorne, C. on behalf of ISOSS. Trends in maternal characteristics and pregnancy outcomes among women living with HIV in the UK: 2014–19. Proceedings of HIV, Glasgow, UK, 23–26 October 2022. [Google Scholar]
- Peters, H.B.L.F.K.; Sconza, R.; Thorne, C. on behalf of ISOSS. Trends in maternal characteristics and pregnancy outcomes among women living with HIV in England: 2015–2020. In Proceedings of the BASHH, Llandudno, North Wales, 26–28 June 2023. [Google Scholar]
- ISOSS. HIV Report 2022. GOV.UK: 2023. Available online: https://www.gov.uk/government/publications/infectious-diseases-in-pregnancy-screening-isoss-hiv-report-2022 (accessed on 30 March 2024).
- Office for National Statistics. Birth Characteristics in England and Wales: 2021. 2023. Available online: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/bulletins/birthcharacteristicsinenglandandwales/2021 (accessed on 30 March 2024).
- Short, C.E.; Douglas, M.; Smith, J.H.; Taylor, G.P. Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission. HIV Med. 2014, 15, 233–238. [Google Scholar] [CrossRef]
- Townsend, C.; Schulte, J.; Thorne, C.; Dominguez, K.I.; Tookey, P.A.; Cortina-Borja, M.; Peckham, C.S.; Bohannon, B.; Newell, M.L.; for the Pediatric Spectrum of HIV Disease Consortium; et al. Antiretroviral therapy and preterm delivery-a pooled analysis of data from the United States and Europe. BJOG Int. J. Obstet. Gynaecol. 2010, 117, 1399–1410. [Google Scholar] [CrossRef]
- Romero, R.; Espinoza, J.; Goncalves, L.F.; Kusanovic, J.P.; Friel, L.; Hassan, S. The role of inflammation and infection in preterm birth. Semin. Reprod. Med. 2007, 25, 21–39. [Google Scholar] [CrossRef]
- Short, C.S.; Brown, R.G.; Quinlan, R.; Lee, Y.S.; Smith, A.; Marchesi, J.R.; Shattock, R.; Bennett, P.R.; Taylor, G.P.; MacIntyre, D.A. Lactobacillus-Depleted Vaginal Microbiota in Pregnant Women Living With HIV-1 Infection Are Associated With Increased Local Inflammation and Preterm Birth. Front. Cell. Infect. Microbiol. 2020, 10, 596917. [Google Scholar] [CrossRef]
- Price, J.T.; Vwalika, B.; France, M.; Ravel, J.; Ma, B.; Mwape, H.; Rittenhouse, K.J.; De Paris, K.; Hobbs, M.; Nelson, J.A.; et al. HIV-associated vaginal microbiome and inflammation predict spontaneous preterm birth in Zambia. Sci. Rep. 2022, 12, 8573. [Google Scholar] [CrossRef]
- Waters, L.; Winston, A.; Reeves, I.; Boffito, M.; Churchill, D.; Cromarty, B.; Dunn, D.; Fink, D.; Fidler, S.; Foster, C.; et al. BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022. HIV Med. 2022, 23 (Suppl. 5), 3–115. [Google Scholar] [CrossRef]
- Khan, M.; Bradshaw, D.; Brown, C.S.; Haddow, J.; Patel, P.; Tosswill, J.H.C.; Pollock, K.; Elliott, T.; Wang, X.; Alagaratnam, J.; et al. Characterization of Rare Spontaneous Human Immunodeficiency Virus Viral Controllers Attending a National United Kingdom Clinical Service Using a Combination of Serology and Molecular Diagnostic Assays. Open Forum Infect. Dis. 2023, 10, ofad108. [Google Scholar] [CrossRef]
- Short, C.E.; Taylor, G.P. Antiretroviral therapy and preterm birth in HIV-infected women. Expert Rev. Anti-Infect. Ther. 2014, 12, 293–306. [Google Scholar] [CrossRef]
- Powis, K.M.; Smeaton, L.; Ogwu, A.; Lockman, S.; Dryden-Peterson, S.; van Widenfelt, E.; Leidner, J.; Makhema, J.; Essex, M.; Shapiro, R.L. Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana. J. Acquir. Immune Defic. Syndr. 2011, 56, 131–138. [Google Scholar] [CrossRef]
- Murray, C.; Portwood, C.; Sexton, H.; Kumarendran, M.; Brandon, Z.; Kirtley, S.; Hemelaar, J. Adverse perinatal outcomes attributable to HIV in sub-Saharan Africa from 1990 to 2020: Systematic review and meta-analyses. Commun. Med. 2023, 3, 103. [Google Scholar] [CrossRef]
- Portwood, C.; Sexton, H.; Kumarendran, M.; Brandon, Z.; Johnson, B.; Kirtley, S.; Hemelaar, J. Perinatal outcomes associated with combination antiretroviral therapy compared with monotherapy. Aids 2023, 37, 489–501. [Google Scholar] [CrossRef]
- Lockman, S.; Brummel, S.S.; Ziemba, L.; Stranix-Chibanda, L.; McCarthy, K.; Coletti, A.; Jean-Philippe, P.; Johnston, B.; Krotje, C.; Fairlie, L.; et al. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): A multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 2021, 397, 1276–1292. [Google Scholar] [CrossRef]
- Zash, R.H.L.; Diseko, M.; Jacobson, D.; Mayondi, G.; Mabuta, J.; Mmalane, M.; Gaolathe, T.; Lockman, S.; Makhema, J.; Shapiro, R. Update on neural tube defects with antiretroviral exposure in the Tsepamo Study, Botswana. In Proceedings of the 24th International AIDS Conference, Montreal, QC, Canada, 29 July–2 August 2022. [Google Scholar]
Live Birth | Pre-2012 n = 35 | Post-2012 n = 14 | p Value |
---|---|---|---|
Median maternal age (years (range)) Missing (n) | 31 (18–37) 3 | 33 (24–40) 5 | 0.05 |
Diagnosed with HIV in current pregnancy (n (%)) | 15 (43) | 2 (14) | 0.10 |
Region of birth Europe Southeast Asia Sub-Saharan Africa Caribbean Missing (n) | women = 23 5 1 16 0 1 | women = 9 2 0 6 1 0 | 0.53 |
Co-morbidity (%) Hepatitis B (n = 2) Hepatitis C (n = 1) Latent TB HTN/GDM | 11 (32) 1 2 1 5 | 12 (86) 1 0 0 2 | 0.001 |
Para (n (%)) 0 1+ | 12 (34) 23 (66) | 2 (14) 12 (86) | 0.29 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Short, C.-E.S.; Byrne, L.; Hagan-Bezgin, A.; Quinlan, R.A.; Anderson, J.; Brook, G.; De Alwis, O.; de Ruiter, A.; Farrugia, P.; Fidler, S.; et al. Pregnancy Management in HIV Viral Controllers: Twenty Years of Experience. Pathogens 2024, 13, 308. https://doi.org/10.3390/pathogens13040308
Short C-ES, Byrne L, Hagan-Bezgin A, Quinlan RA, Anderson J, Brook G, De Alwis O, de Ruiter A, Farrugia P, Fidler S, et al. Pregnancy Management in HIV Viral Controllers: Twenty Years of Experience. Pathogens. 2024; 13(4):308. https://doi.org/10.3390/pathogens13040308
Chicago/Turabian StyleShort, Charlotte-Eve S., Laura Byrne, Aishah Hagan-Bezgin, Rachael A. Quinlan, Jane Anderson, Gary Brook, Okavas De Alwis, Annemiek de Ruiter, Pippa Farrugia, Sarah Fidler, and et al. 2024. "Pregnancy Management in HIV Viral Controllers: Twenty Years of Experience" Pathogens 13, no. 4: 308. https://doi.org/10.3390/pathogens13040308
APA StyleShort, C.-E. S., Byrne, L., Hagan-Bezgin, A., Quinlan, R. A., Anderson, J., Brook, G., De Alwis, O., de Ruiter, A., Farrugia, P., Fidler, S., Hamlyn, E., Hartley, A., Murphy, S., Noble, H., Oomeer, S., Roedling, S., Rosenvinge, M., Rubinstein, L., Shah, R., ... Taylor, G. P. (2024). Pregnancy Management in HIV Viral Controllers: Twenty Years of Experience. Pathogens, 13(4), 308. https://doi.org/10.3390/pathogens13040308